Administrative Core

行政核心

• 批准号: 7983109
• 负责人: MAURO FERRARI
• 金额: $ 46.61万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7983109
• 关键词: Advisory Committees; Appointment; Award; Biomedical Engineering; Blood Vessels; Budgets; CCNE1 gene; Cancer Biology; Cancer Research Project; Chairperson; Clinical Oncology; Clinical Sciences; Commit; Communication; Computer software; Core Facility; Development; Education and Outreach; Educational workshop; Engineering; Equipment and Supplies; Evaluation; Event; Faculty; Functional RNA; Funding; Grant; Gynecologic Oncology; Human Resources; Institution; Internet; Lead; Leadership; Liposomes; Maintenance; Malignant Neoplasms; Malignant neoplasm of ovary; Mathematics; Mechanics; Medicine; Methods; Monitor; Nanotechnology; Pharmacologic Substance; Physicians; Pilot Projects; Play; Postdoctoral Fellow; Principal Investigator; Process; Program Development; Progress Reports; Publications; RNA Interference; Reporting; Research; Research Infrastructure; Research Personnel; Resources; Rice; Role; Schedule; Secure; Seeds; Site Visit; Small Interfering RNA; Specialist; Teleconferences; Therapeutic; Time; Training; Training Programs; Travel; United States National Aeronautics and Space Administration; Universities; University of Texas M D Anderson Cancer Center; Work; austin; data management; data sharing; experience; in vivo; malignant breast neoplasm; meetings; nanomedicine; nanoparticle; novel; oncology; operation; outreach program; physical science; professor; programs; symposium; training project; web site

Organization and Functions of the Administrative Core (CAdmin). As a Principal Investigator of the proposed TCCN, Dr. Mauro Ferrari is Chairman of the Department of Nanomedicine and Biomedical Engineering (nBME). Dr. Ferrari holds concurrent faculty appointments at MDACC (tenured Full Professor, Experimental Therapeutics), Rice University (Bioengineering) and UT Austin (Biomedical Engineering), and is the President of the Alliance for NanoHealth (ANH). Dr. Ferrari is trained in mathematics, mechanical engineering and medicine. He is a recognized leader in the development and applicafion of biomedical nanotechnology. Among many awards he received. Dr. Ferrari is the recipient of the DoD CDMRP Breast Cancer Research Program's Innovator Award in 2008. Co-leading the TCCN as Principal Invesfigator is Dr. Anil K. Sood of MDACC, Professor and Director ofthe Blanton-Davis Ovarian Cancer Research Program in the Departments of Gynecologic Oncology and Cancer Biology. He is also the Director of the Center for RNA Interference and Non-Coding RNA at MDACC. Dr. Sood is a renowned physician scienfist known for his research on the systemic in vivo siRNA delivery using biocompafible nanoparticles and development of novel anti-vascular therapeufic approaches. Dr. Gabriel Lopez-Berestein Is the third Principal Investigator, and is currently Professor of Medicine and Cancer Biology, Department of Experimental Therapeutics, Division of Cancer Medicine, MDACC; Executive Director, PDC at MDACC and Adjunct Professor at Rice University (Bioengineering). Dr. Lopez-Berestein is a widely recognized expert in the field of liposomal therapeufics and in translafional research. TCCN Administrative Core will be advised by Dr. Raymond DuBois, Other Significant Contributor of TCCN and Provost/Executive Vice President of MDACC. Drs. Ferrari, Sood, and Lopez-Berestein will lead the TCCN from the perspecfives of applied nanotechnology, clinical oncology, and translational work for pharmaceutical development, respectively. Each of them has demonstrated experience to conduct and lead mulfidisciplinary research programs that bridge the physical sciences and biomedical and clinical sciences. The CAdmin led by the Pis will be assisted by a Center Manager, Dr. Jason Sakamoto, to provide leadership and general administration for all activities related to this TCCN. In particular, CAdmin is responsible for: 1) providing administrafive support to all projects and core resources of the TCCN, 2) providing administrative support to develop and manage pilot project programs (Internal pilot projects and Trans-Alliance challenge projects), 3) convening TCCN team meetings, advisory committee meetings, as well as scientific conferences and workshops, 4) supporting the participation of the TCCN in the NCI Alliance for Nanotechnology in Cancer and communicate with NCI staff, facilitate and prepare the TCCN participation in NCI evaluafion, 5) facilitafing communication with other CCNE programs, and among other administrafive and supportive funcfions, and 6) interfacing with other administrative resources (ANH and nBME) and shared core facilities in the participating institutions.

行政核心（CAdmin）的组织和职能。作为拟议TCCN的主要研究员，Mauro Ferrari博士是纳米医学和生物医学工程（nBME）系主任。Ferrari博士同时在MDACC（终身教授，实验治疗学），莱斯大学（生物工程）和UT Austin（生物医学工程）担任教职，并且是纳米健康联盟（ANH）的主席。Ferrari博士接受过数学、机械工程和医学方面的培训。他是生物医学纳米技术开发和应用领域公认的领导者。在他获得的众多奖项中。Ferrari博士是2008年DoD CDMRP乳腺癌研究计划创新者奖的获得者。共同领导TCCN作为主要投资者是博士。MDACC的Sood教授，妇科肿瘤学和癌症生物学系Blanton-Davis卵巢癌研究项目主任。他也是MDACC RNA干扰和非编码RNA中心的主任。Sood博士是一位著名的科学家，以其使用生物相容性纳米颗粒进行体内siRNA系统递送的研究和开发新型抗血管治疗方法而闻名。Gabriel Lopez-Berestein博士是第三位主要研究者，目前是MDACC癌症医学部实验治疗学系医学和癌症生物学教授; MDACC PDC执行董事和莱斯大学兼职教授（生物工程）。Lopez-Berestein博士是脂质体治疗和药物研究领域的公认专家。TCCN行政核心将由TCCN的其他重要贡献者和MDACC的教务长/执行副总裁Raymond DuBois博士提供咨询。 Drs.法拉利，Sood和Lopez-Berestein将从应用的角度领导TCCN 纳米技术、临床肿瘤学和药物开发的转化工作。他们每个人都表现出经验，进行和领导跨学科的研究计划，桥梁物理科学和生物医学和临床科学。由PI领导的CAdmin将由中心经理Jason Sakamoto博士协助，为与该TCCN相关的所有活动提供领导和一般管理。具体而言，CAdmin负责：1）为TCCN的所有项目和核心资源提供行政支持，2）为开发和管理试点项目提供行政支持（内部试点项目和跨联盟挑战项目），3）召开TCCN团队会议、咨询委员会会议以及科学会议和研讨会，4）支持TCCN参与NCI癌症纳米技术联盟，并与NCI工作人员沟通，促进和准备TCCN参与NCI评估，5）促进与其他CCNE计划的沟通，以及其他管理和支持功能，和6）与其他行政资源（ANH和nBME）和参与机构的共享核心设施接口。